Don't Sleep On DTC Compliance: FDA Dings Zolpimist Superiority Claim Vs Ambien
Executive Summary
Warning letter objects to webpage and meeting exhibit material for excluding any risk information and suggesting mist formulation is superior to oral zolpidem products.
You may also be interested in...
Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017
Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.
Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study
US agency disagrees that study of consumer and healthcare professional ability to detect deceptive promos is unnecessary; final guidance on product name placement in labeling and advertisements mirrors 2013 draft.
Opioid Warning Letter To Cipher Likely Easy Call For US FDA
Murky enforcement environment has probably contributed to FDA's record-low number of letters, but detailing material for ConZip failed to include risk information and important limitations of use for the tramadol extended-release product.